Loss of the PTCH1 tumor suppressor defines a new subset of plexiform fibromyxoma

Sudeep Banerjee, Christopher Corless, Markku M. Miettinen, Sangkyu Noh, Rowan Ustoy, Jessica L. Davis, Chih Min Tang, Mayra Yebra, Adam M. Burgoyne, Jason K. Sicklick

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Plexiform fibromyxoma (PF) is a rare gastric tumor often confused with gastrointestinal stromal tumor. These so-called "benign" tumors often present with upper GI bleeding and gastric outlet obstruction. It was recently demonstrated that approximately one-third of PF have activation of the GLI1 oncogene, a transcription factor in the hedgehog (Hh) pathway, via a MALAT1-GLI1 fusion protein or GLI1 up-regulation. Despite this discovery, the biology of most PFs remains unknown. METHODS: Next generation sequencing (NGS) was performed on formalin-fixed paraffin-embedded (FFPE) samples of PF specimens collected from three institutions (UCSD, NCI and OHSU). Fresh frozen tissue from one tumor was utilized for in vitro assays, including quantitative RT-PCR and cell viability assays following drug treatment. RESULTS: Eight patients with PF were identified and 5 patients' tumors were analyzed by NGS. An index case had a mono-allelic PTCH1 deletion of exons 15-24 and a second case, identified in a validation cohort, also had a PTCH1 gene loss associated with a suspected long-range chromosome 9 deletion. Building on the role of Hh signaling in PF, PTCH1, a tumor suppressor protein, functions upstream of GLI1. Loss of PTCH1 induces GLI1 activation and downstream gene transcription. Utilizing fresh tissue from the index PF case, RT-qPCR analysis demonstrated expression of Hh pathway components, SMO and GLI1, as well as GLI1 transcriptional targets, CCND1 and HHIP. In turn, short-term in vitro treatment with a Hh pathway inhibitor, sonidegib, resulted in dose-dependent cell killing. CONCLUSIONS: For the first time, we report a novel association between PTCH1 inactivation and the development of plexiform fibromyxoma. Hh pathway inhibition with SMO antagonists may represent a target to study for treating a subset of plexiform fibromyxomas.

Original languageEnglish (US)
Number of pages1
JournalJournal of translational medicine
Volume17
Issue number1
DOIs
StatePublished - Jul 30 2019

Fingerprint

Fibroma
Tumors
Neoplasms
Assays
Genes
Chemical activation
Cells
Tissue
Tumor Suppressor Proteins
Drug therapy
Transcription
Chromosomes
Paraffin
Formaldehyde
Gastric Outlet Obstruction
Exons
Transcription Factors
Fusion reactions
Chromosome Deletion
Chromosomes, Human, Pair 9

Keywords

  • Gastric mass
  • Gastrointestinal stromal tumor
  • GLI1
  • Hedgehog pathway
  • Next generation sequencing
  • Patched 1
  • SMO inhibitor
  • Sonidegib
  • Submucosal tumor

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Loss of the PTCH1 tumor suppressor defines a new subset of plexiform fibromyxoma. / Banerjee, Sudeep; Corless, Christopher; Miettinen, Markku M.; Noh, Sangkyu; Ustoy, Rowan; Davis, Jessica L.; Tang, Chih Min; Yebra, Mayra; Burgoyne, Adam M.; Sicklick, Jason K.

In: Journal of translational medicine, Vol. 17, No. 1, 30.07.2019.

Research output: Contribution to journalArticle

Banerjee, S, Corless, C, Miettinen, MM, Noh, S, Ustoy, R, Davis, JL, Tang, CM, Yebra, M, Burgoyne, AM & Sicklick, JK 2019, 'Loss of the PTCH1 tumor suppressor defines a new subset of plexiform fibromyxoma', Journal of translational medicine, vol. 17, no. 1. https://doi.org/10.1186/s12967-019-1995-z
Banerjee, Sudeep ; Corless, Christopher ; Miettinen, Markku M. ; Noh, Sangkyu ; Ustoy, Rowan ; Davis, Jessica L. ; Tang, Chih Min ; Yebra, Mayra ; Burgoyne, Adam M. ; Sicklick, Jason K. / Loss of the PTCH1 tumor suppressor defines a new subset of plexiform fibromyxoma. In: Journal of translational medicine. 2019 ; Vol. 17, No. 1.
@article{43577a65c69e4d38b1be9e66ccd90d51,
title = "Loss of the PTCH1 tumor suppressor defines a new subset of plexiform fibromyxoma",
abstract = "BACKGROUND: Plexiform fibromyxoma (PF) is a rare gastric tumor often confused with gastrointestinal stromal tumor. These so-called {"}benign{"} tumors often present with upper GI bleeding and gastric outlet obstruction. It was recently demonstrated that approximately one-third of PF have activation of the GLI1 oncogene, a transcription factor in the hedgehog (Hh) pathway, via a MALAT1-GLI1 fusion protein or GLI1 up-regulation. Despite this discovery, the biology of most PFs remains unknown. METHODS: Next generation sequencing (NGS) was performed on formalin-fixed paraffin-embedded (FFPE) samples of PF specimens collected from three institutions (UCSD, NCI and OHSU). Fresh frozen tissue from one tumor was utilized for in vitro assays, including quantitative RT-PCR and cell viability assays following drug treatment. RESULTS: Eight patients with PF were identified and 5 patients' tumors were analyzed by NGS. An index case had a mono-allelic PTCH1 deletion of exons 15-24 and a second case, identified in a validation cohort, also had a PTCH1 gene loss associated with a suspected long-range chromosome 9 deletion. Building on the role of Hh signaling in PF, PTCH1, a tumor suppressor protein, functions upstream of GLI1. Loss of PTCH1 induces GLI1 activation and downstream gene transcription. Utilizing fresh tissue from the index PF case, RT-qPCR analysis demonstrated expression of Hh pathway components, SMO and GLI1, as well as GLI1 transcriptional targets, CCND1 and HHIP. In turn, short-term in vitro treatment with a Hh pathway inhibitor, sonidegib, resulted in dose-dependent cell killing. CONCLUSIONS: For the first time, we report a novel association between PTCH1 inactivation and the development of plexiform fibromyxoma. Hh pathway inhibition with SMO antagonists may represent a target to study for treating a subset of plexiform fibromyxomas.",
keywords = "Gastric mass, Gastrointestinal stromal tumor, GLI1, Hedgehog pathway, Next generation sequencing, Patched 1, SMO inhibitor, Sonidegib, Submucosal tumor",
author = "Sudeep Banerjee and Christopher Corless and Miettinen, {Markku M.} and Sangkyu Noh and Rowan Ustoy and Davis, {Jessica L.} and Tang, {Chih Min} and Mayra Yebra and Burgoyne, {Adam M.} and Sicklick, {Jason K.}",
year = "2019",
month = "7",
day = "30",
doi = "10.1186/s12967-019-1995-z",
language = "English (US)",
volume = "17",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Loss of the PTCH1 tumor suppressor defines a new subset of plexiform fibromyxoma

AU - Banerjee, Sudeep

AU - Corless, Christopher

AU - Miettinen, Markku M.

AU - Noh, Sangkyu

AU - Ustoy, Rowan

AU - Davis, Jessica L.

AU - Tang, Chih Min

AU - Yebra, Mayra

AU - Burgoyne, Adam M.

AU - Sicklick, Jason K.

PY - 2019/7/30

Y1 - 2019/7/30

N2 - BACKGROUND: Plexiform fibromyxoma (PF) is a rare gastric tumor often confused with gastrointestinal stromal tumor. These so-called "benign" tumors often present with upper GI bleeding and gastric outlet obstruction. It was recently demonstrated that approximately one-third of PF have activation of the GLI1 oncogene, a transcription factor in the hedgehog (Hh) pathway, via a MALAT1-GLI1 fusion protein or GLI1 up-regulation. Despite this discovery, the biology of most PFs remains unknown. METHODS: Next generation sequencing (NGS) was performed on formalin-fixed paraffin-embedded (FFPE) samples of PF specimens collected from three institutions (UCSD, NCI and OHSU). Fresh frozen tissue from one tumor was utilized for in vitro assays, including quantitative RT-PCR and cell viability assays following drug treatment. RESULTS: Eight patients with PF were identified and 5 patients' tumors were analyzed by NGS. An index case had a mono-allelic PTCH1 deletion of exons 15-24 and a second case, identified in a validation cohort, also had a PTCH1 gene loss associated with a suspected long-range chromosome 9 deletion. Building on the role of Hh signaling in PF, PTCH1, a tumor suppressor protein, functions upstream of GLI1. Loss of PTCH1 induces GLI1 activation and downstream gene transcription. Utilizing fresh tissue from the index PF case, RT-qPCR analysis demonstrated expression of Hh pathway components, SMO and GLI1, as well as GLI1 transcriptional targets, CCND1 and HHIP. In turn, short-term in vitro treatment with a Hh pathway inhibitor, sonidegib, resulted in dose-dependent cell killing. CONCLUSIONS: For the first time, we report a novel association between PTCH1 inactivation and the development of plexiform fibromyxoma. Hh pathway inhibition with SMO antagonists may represent a target to study for treating a subset of plexiform fibromyxomas.

AB - BACKGROUND: Plexiform fibromyxoma (PF) is a rare gastric tumor often confused with gastrointestinal stromal tumor. These so-called "benign" tumors often present with upper GI bleeding and gastric outlet obstruction. It was recently demonstrated that approximately one-third of PF have activation of the GLI1 oncogene, a transcription factor in the hedgehog (Hh) pathway, via a MALAT1-GLI1 fusion protein or GLI1 up-regulation. Despite this discovery, the biology of most PFs remains unknown. METHODS: Next generation sequencing (NGS) was performed on formalin-fixed paraffin-embedded (FFPE) samples of PF specimens collected from three institutions (UCSD, NCI and OHSU). Fresh frozen tissue from one tumor was utilized for in vitro assays, including quantitative RT-PCR and cell viability assays following drug treatment. RESULTS: Eight patients with PF were identified and 5 patients' tumors were analyzed by NGS. An index case had a mono-allelic PTCH1 deletion of exons 15-24 and a second case, identified in a validation cohort, also had a PTCH1 gene loss associated with a suspected long-range chromosome 9 deletion. Building on the role of Hh signaling in PF, PTCH1, a tumor suppressor protein, functions upstream of GLI1. Loss of PTCH1 induces GLI1 activation and downstream gene transcription. Utilizing fresh tissue from the index PF case, RT-qPCR analysis demonstrated expression of Hh pathway components, SMO and GLI1, as well as GLI1 transcriptional targets, CCND1 and HHIP. In turn, short-term in vitro treatment with a Hh pathway inhibitor, sonidegib, resulted in dose-dependent cell killing. CONCLUSIONS: For the first time, we report a novel association between PTCH1 inactivation and the development of plexiform fibromyxoma. Hh pathway inhibition with SMO antagonists may represent a target to study for treating a subset of plexiform fibromyxomas.

KW - Gastric mass

KW - Gastrointestinal stromal tumor

KW - GLI1

KW - Hedgehog pathway

KW - Next generation sequencing

KW - Patched 1

KW - SMO inhibitor

KW - Sonidegib

KW - Submucosal tumor

UR - http://www.scopus.com/inward/record.url?scp=85070833178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070833178&partnerID=8YFLogxK

U2 - 10.1186/s12967-019-1995-z

DO - 10.1186/s12967-019-1995-z

M3 - Article

C2 - 31362756

AN - SCOPUS:85070833178

VL - 17

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

ER -